Journal
BIOANALYSIS
Volume 8, Issue 10, Pages 1009-1020Publisher
FUTURE SCI LTD
DOI: 10.4155/bio-2016-0018
Keywords
clinical pharmacokinetics; LC-MS bioanalysis; nSMOL
Funding
- Ministry of Health and Labor Sciences Research of Japan
Ask authors/readers for more resources
Background: We recently reported the principle of nano-surface and molecular-orientation limited (nSMOL) proteolysis, which is useful for LC-MS bioanalysis of antibody drugs. Methodology: The nSMOL is a Fab-selective limited proteolysis which utilizes the difference of protease-immobilized nanoparticle diameter (200 nm) and antibody collection resin pore (100 nm). We have demonstrated the full validation for chimeric antibody cetuximab bioanalysis in human plasma using nSMOL. Signature peptides (SQVFFK, ASQSIGTNIHWYQQR and YASESISGIPSR) in cetuximab complementarity-determining region were simultaneously quantitated by LC-MS multiple reaction monitoring. Conclusion: This nSMOL quantification showed sensitivity of 0.586 mu g/ml and linearity of 0.586 to 300 mu g/ml. Full validation study archived the guideline criteria of low Mw drug compounds. These results indicate that nSMOL is also significant method for cetuximab bioanalysis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available